Ipsen pens $1.7B deal to acquire Kartos for potential Jakafi add-on therapy for myelofibrosis - Fierce Biotech
Ipsen is paying $450 million upfront to buy U.S.-based | Ipsen is paying $450 million upfront to buy U.S.-based Kartos Therapeutics for a phase 3-stage blood cancer drug designed to improve Jakafi treatment.
Comments